Recent advances in the treatment landscape of the rare hematologic disease indolent systemic mastocytosis (ISM) have provided patients a more targeted approach to therapy. The multisystemic nature of ISM makes effective management challenging, often requiring a team of specialists and multiple concurrent therapies. Treatment and management plans are individualized for each patient with ISM, accounting for specific symptoms, genetic mutations, triggers, disease severity, and responses to previous therapies. In this video, hear experts discuss treatment options for ISM from mediator symptom-directed therapies to disease-targeted agents and evidence-based strategies for optimizing personalized treatment. Additionally, hear impactful testimony from two patients with ISM concerning their challenges with treatment and management for ISM.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/on-demand-mastery-roles-polypharmacy-novel-therapies-individualized-management
- Start Date: 2024-05-17 05:00:00
- End Date: 2024-05-17 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Blueprint Medicines - Amount: 43166.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all